Cytokinetics, Incorporated (CYTK)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 1.9M | 17.8M | 19.4M | 28.6M |
| Gross Profit | (97.3M) | (86.6M) | 16.8M | 23.0M |
| Operating Income | (166.8M) | (178.4M) | (183.6M) | (179.2M) |
| Net Income | (306.2M) | (183.0M) | (206.0M) | (198.8M) |
| Diluted EPS | $-2.55 | $-1.50 | $-1.67 | $-1.50 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 94.6M | 7.5M | 18.5M | 88.0M |
| Gross Profit | (146.2M) | (322.6M) | (320.9M) | (328.0M) |
| Operating Income | (324.2M) | (496.2M) | (536.2M) | (612.3M) |
| Net Income | (389.0M) | (526.2M) | (589.5M) | (785.0M) |
| Diluted EPS | $-4.33 | $-5.45 | $-5.26 | $-6.54 |